Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.58% is 103% above its 4-year average of -201.33%, near the high end of its 4-year range (-707.22%–6.58%).
As of the fiscal period ended Tuesday, June 30, 2026. 105.60% above its 12-month average of -117.47%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.58%.
RETURN ON EQUITY (ROE)
6.58%
RETURN ON EQUITY (ROE) AVG TTM
-117.47%
RETURN ON EQUITY (ROE) AVG 3Y
-253.92%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+105.60%
CURRENT VS 3Y AVG
+102.59%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.35%
median of 344 covered companies
CURRENT VS SECTOR MEDIAN
+120.99%
vs the sector median at left
CDT Equity Inc.
Market Cap
$707297.00
Return on Equity (ROE)
6.58%
TTM Avg
-117.47%
3Y Avg
-253.92%
5Y Avg
N/A
Market Cap
$787624.00
Return on Equity (ROE)
-77.23%
TTM Avg
-124.66%
3Y Avg
-168.43%
5Y Avg
-110.88%
Market Cap
$878396.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$885939.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$888387.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$1.02M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$1.11M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$61819.00
Return on Equity (ROE)
N/A
TTM Avg
163.76%
3Y Avg
281.78%
5Y Avg
257.03%
Market Cap
$1.36M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CDT Equity Inc. (CDT) | $707297.00 | 6.58% | -117.47% | -253.92% | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -77.23% | -124.66% | -168.43% | -110.88% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | -255.88% | -273.58% | -200.54% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | -57.87% | -222.45% | -164.72% | -135.78% |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A | 163.76% | 281.78% | 257.03% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | -253.57% | 334.28% | 134.39% | 95.16% |
| Genprex, Inc. (GNPX)vs › | $1.37M | -111.51% | -753.43% | -507.39% | -356.28% |
ROE
6.6%
ROA
2.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 6.58% |
| 2026-03-29 | 1.29% |
| 2025-12-31 | -3.10% |
| 2025-09-28 | -474.64% |
| 2025-06-29 | -556.76% |
| 2025-03-30 | -707.22% |
| 2023-06-30 | -43.62% |
| 2023-03-31 | -33.46% |
| 2022-09-30 | -1.05% |
